Photo:
utswmed.org
Mar 5, 2026, 15:51
Samer Al Hadidi: Cytopenias and Infection Risk With BCMA-Directed Bispecific Antibodies
Samer Al Hadidi, Associate Professor at UT Southwestern Medical Center, shared a post on LinkedIn:
“The Overlooked Burden of Cytopenias With BCMA-Directed Bispecific Antibodies
Hematologic toxicity is underappreciated:
- 87% of pts: grade 3-4 lymphopenia
- 55% grade 3-4 neutropenia (65% with teclistamab)
- 74% required dose interruptions
- 54.5% needed G-CSF
This is likely one of the important causes of higher grade infections with those agents.
We need to think about preventive strategies given the high efficacy of those agents.”
Stay updated with Hemostasis Today.
-
Apr 22, 2026, 17:19Ralf Ludwig: Bridging Population Data and Immunology in Inflammatory Diseases
-
Apr 22, 2026, 17:15Giacomo Rossi: Genetic Study Reveals 10 Genes in Hyperemesis Gravidarum
-
Apr 22, 2026, 17:06Maura Boerio: Quantifying Barriers to Care in Vascular Ehlers-Danlos Syndrome
-
Apr 22, 2026, 17:05Kausik Ray։ Metabolically Healthy Obesity Is Being Re-Evaluated as a High-Risk Condition Needing Closer Attention
-
Apr 22, 2026, 16:58Baba-Jallah Epega: Sickle Cell Resilience Through Patient Voices and Clinical Insight
-
Apr 22, 2026, 16:44Francisco Chacón-Lozsán: Cytokine Storm Is Not Just Inflammation, It Is Organ Failure in Motion
-
Apr 22, 2026, 16:29CBTH 2026 Opens with First Workshop in Germany – European Hematology Association
-
Apr 22, 2026, 16:16Christopher Pittman: Superficial Venous Disease Needs Arterial-Level Follow-Up
-
Apr 22, 2026, 15:47Mohammed Alo: Being Fit Does Not Protect You from High LDL